{"id":991828,"date":"2026-08-06T23:25:14","date_gmt":"2026-08-07T03:25:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/"},"modified":"2026-08-06T23:25:14","modified_gmt":"2026-08-07T03:25:14","slug":"lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/","title":{"rendered":"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Aug.  06, 2026  (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) (\u201cSummit\u201d or the \u201cCompany\u201d) breached their fiduciary duties to shareholders in connection with a $520 million loan transaction between the Company and its Executive Chairman, Robert W. Duggan.<\/p>\n<p align=\"justify\">According to an unsealed lawsuit, Duggan forced Summit into a \u201cplainly usurious\u201d $520 million loan that allowed Duggan and his wife, Mahkam Zanganeh, to extract approximately $114 million from the Company. An investor has filed suit challenging the transaction, alleging that Duggan and Zanganeh exploited their control over Summit to manipulate the terms and timing of a bridge loan repayable in millions of additional shares, and pegged the financing to the Company\u2019s trading price shortly before a lucrative drug-licensing agreement with Akeso, Inc. sent Summit\u2019s stock price higher.<\/p>\n<p align=\"justify\">\u201cOur investigation concerns whether certain officers and directors of Summit Therapeutics engaged in self-dealing at the expense of the Company and its shareholders,\u201d said attorney Andrea Farah, Lowey Dannenberg, P.C. partner and head of the firm\u2019s securities practice.<\/p>\n<p align=\"justify\">Affected shareholders may be entitled to damages and corporate governance reforms as a result of this alleged misconduct, which raises serious questions about the integrity of Summit\u2019s internal management and controls.<\/p>\n<p align=\"justify\">If you are a current Summit Therapeutics shareholder and wish to learn more about this investigation, or about your rights and options, contact our attorneys Andrea Farah (afarah@lowey.com) at (914) 733-7256 or Vincent R. Cappucci Jr. (vcappucci@lowey.com) at (914) 733-7278.<\/p>\n<p>About Lowey Dannenberg<\/p>\n<p align=\"justify\">Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.<\/p>\n<p>Contact<\/p>\n<p>Lowey Dannenberg P.C.<br \/>44 South Broadway, Suite 1100<br \/>White Plains, NY 10601<br \/>Tel: (914) 733-7256<br \/>Email: investigations@lowey.com<\/p>\n<p>SOURCE: Lowey Dannenberg<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZThiYTBjMGMtODRhYy00NzBkLWEwNTUtOTQxMmNjZWMxYWQxLTEyMDYwODctMjAyNi0wOC0wNi1lbg==\/tiny\/Lowey-Dannenberg-P-C-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) (\u201cSummit\u201d or the \u201cCompany\u201d) breached their fiduciary duties to shareholders in connection with a $520 million loan transaction between the Company and its Executive Chairman, Robert W. Duggan. According to an unsealed lawsuit, Duggan forced Summit into a \u201cplainly usurious\u201d $520 million loan that allowed Duggan and his wife, Mahkam Zanganeh, to extract approximately $114 million from the Company. An investor has filed suit challenging the transaction, alleging that Duggan and Zanganeh exploited their control over Summit to manipulate the terms and timing of a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-991828","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) (\u201cSummit\u201d or the \u201cCompany\u201d) breached their fiduciary duties to shareholders in connection with a $520 million loan transaction between the Company and its Executive Chairman, Robert W. Duggan. According to an unsealed lawsuit, Duggan forced Summit into a \u201cplainly usurious\u201d $520 million loan that allowed Duggan and his wife, Mahkam Zanganeh, to extract approximately $114 million from the Company. An investor has filed suit challenging the transaction, alleging that Duggan and Zanganeh exploited their control over Summit to manipulate the terms and timing of a &hellip; Continue reading &quot;Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-07T03:25:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty\",\"datePublished\":\"2026-08-07T03:25:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/\"},\"wordCount\":352,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/\",\"name\":\"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ=\",\"datePublished\":\"2026-08-07T03:25:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/","og_locale":"en_US","og_type":"article","og_title":"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty - Market Newsdesk","og_description":"NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) (\u201cSummit\u201d or the \u201cCompany\u201d) breached their fiduciary duties to shareholders in connection with a $520 million loan transaction between the Company and its Executive Chairman, Robert W. Duggan. According to an unsealed lawsuit, Duggan forced Summit into a \u201cplainly usurious\u201d $520 million loan that allowed Duggan and his wife, Mahkam Zanganeh, to extract approximately $114 million from the Company. An investor has filed suit challenging the transaction, alleging that Duggan and Zanganeh exploited their control over Summit to manipulate the terms and timing of a &hellip; Continue reading \"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-07T03:25:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty","datePublished":"2026-08-07T03:25:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/"},"wordCount":352,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/","name":"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ=","datePublished":"2026-08-07T03:25:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNTYzNyM3NzY0MDk4IzIxOTQ1MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lowey-dannenberg-p-c-is-investigating-summit-therapeutics-inc-nasdaq-smmt-for-potential-breaches-of-fiduciary-duty\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/991828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=991828"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/991828\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=991828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=991828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=991828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}